Email the author Inflammatory Markers upon Admission as Predictors of Outcome in COVID-19 Patients
Abstract
Background: Coronavirus disease 2019 (COVID-19) may cause dysregulation of the immune system, leading to hyperinflammation. Inflammatory markers can be used to predict in-hospital mortality in COVID-19 patients. This research was aimed to investigate the association between the levels of various inflammatory markers and mortality in COVID-19 patients.
Methods: This study was conducted at Persahabatan National Respiratory Referral Hospital, Indonesia. Blood tests were performed upon admission, measuring the C-reactive protein, PCT, leukocyte, differential counts, and platelet count. The outcome measured was the mortality of hospitalized COVID-19 patients. Statistical analysis methods included the Mann–Whitney U test, receiver operating characteristic (ROC) analysis, and area under the curve (AUC) test.
Results: Total 110 patients were included, and the laboratory values were analyzed to compare survivors and non-survivors. The non-survivor group had significantly higher leukocyte count, lower lymphocyte count, higher CRP and PCT levels, higher neutrophil-to-lymphocyte ratio (NLR), higher platelet-to-lymphocyte ratio (PLR), and lower lymphocyte-to-CRP ratio. As predictors of mortality, AUC analysis revealed that PCT, CRP, NLR, and PLR had AUCs of 0.867, 0.82, 0.791, and 0.746, respectively.
Conclusions: Routine and affordable inflammatory markers tested on admission may be useful as predictors of in-hospital mortality in COVID-19 patients requiring hospitalization.Keywords
Full Text:
PDFReferences
CDC. Coronavirus Disease 2019 (COVID-19) [Internet]; 2020. [Cited Mar 23 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html. Centers for Disease Control and Prevention.
Features, evaluation and treatment coronavirus (COVID-19) - StatPearls - NCBI bookshelf [Internet]. [Cited Apr 3 2020]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.
Coronavirus COVID-19. nCoV) [Internet]; 2019–. [Cited Apr 30 2020]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020 Mar 1;55(3):105924.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020 Mar 23. [Cited Apr 30 2020]. Available from: https://jamanetwork.com/journals/jama/fullarticle/2763667;323(18):1775–6.
Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med 2020 Mar 23;382:2049–55.
How A. South Korean city is changing tactics to tamp down its COVID-19 surge [Internet]. NPR. Org. [Cited Apr 30 2020]. Available from: https://www.npr.org/sections/goatsandsoda/2020/03/10/812865169/how-a-south-korean-city-is-changing-tactics-to-tamp-down-its-covid-19-surge.
Moghadas SM, Shoukat A, Fitzpatrick MC, Wells CR, Sah P, Pandey A, et al. Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proc Natl Acad Sci U S A 2020 Apr 21;117(16):9122–6.
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 2020 Mar 21;395(10228):931–4.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis Off Publ Infect Dis Soc Am 2020 Mar 12;71(15):762–8.
Gürağaç A, Demirer Z. The neutrophil-to-lymphocyte ratio in clinical practice. Can Urol Assoc J 2016;10(3–4):141.
Liu X, Shen Y, Wang H, Ge Q, Fei A, Pan S. Prognostic significance of neutrophil-to-lymphocyte ratio in patients with sepsis: A prospective observational study [Internet]. Mediators Inflam 2016 [Cited Apr 30 2020]. Hindawi;2016:8191254. Available from: https://www.hindawi.com/journals/mi/2016/8191254/.
Sinclair AJ, Abdelhafiz AH. Age, frailty and diabetes – Triple jeopardy for vulnerability to COVID-19 infection. EClinicalmedicine 2020 May 1 [Cited Jun 21 2020];22. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30087-0/abstract:100343.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020 May 26;323(20):2052–9.
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract 2020 Apr 1;162:108142.
Knapp S. Diabetes and infection: Is there a link? - A mini-review. Gerontology 2013;59(2):99–104.
Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study. Eur Heart J 2020 Jun 7;41(22):2058–66.
Luan YY, Dong N, Xie M, Xiao XZ, Yao YM. The significance and regulatory mechanisms of innate immune cells in the development of sepsis. J Interferon Cytokine Res 2014 Jan 1;34(1):2–15.
Lee JS, Kim NY, Na SH, Youn YH, Shin CS. Reference values of neutrophil–lymphocyte ratio, lymphocyte–monocyte ratio, platelet–lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Med (Baltim) 2018 Jun 29 [Cited Oct 9 2020];97(26). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039688/:e11138.
Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020 Jul;84:106504.
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020 Jun 1;50(4):332–4.
Yan L, Zhang H-T, Goncalves J, Xiao Y, Wang M, Guo Y, et al. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell 2020 May;2(5):283–8.
Cheng CB, Zhang QX, Zhuang LP, Sun JW. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: A multicentre study. Jpn J Clin Oncol. [Cited Jun 25 2020]. Available from: https://academic.oup.com/jjco/advance-article/doi/10.1093/jjco/hyaa099/5860131 2020;50(10):1141–9.
Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg 2020 Feb 16;272(2):342–51.
Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ichikawa T, Yin C, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clin Nutr 2020 Apr 1;39(4):1209–17.
Lagunas‐Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol [Internet]. [cited 2020 Apr 30];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25819
Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol [Internet]. 2018 Apr 13 [cited 2020 Jun 25];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908901/
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta Int J Clin Chem 2020 Jun;505:190–1.
What is the reference range of procalcitonin (PCT)? [Internet]. [Cited Oct 9 2020]. Available from: https://www.medscape.com/answers/2096589-179637/what-is-the-reference-range-of-procalcitonin-pct.
Reference values in sepsis - B·R·A·H·M·S PCT (procalcitonin) [Internet]. [Cited Oct 9 2020]. Available from: https://www.procalcitonin.com/clinical-utilities/sepsis/reference-values-sepsis.html.
DOI: https://doi.org/10.36497/jri.v41i4.185
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Budhi Antariksa, Erlina Burhan, Agus Dwi Susanto, Mohamad Fahmi Alatas, Feni Fitriani Taufik, Dewi Yennita Sari, Dicky Soehardiman, Andika Chandra Putra, Erlang Samoedro, Ibrahim Nur Insan Putra Darmawan, Hera Afidjati, Muhammad Alkaff, Rita Rogayah
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-ShareAlike 4.0 International License Statcounter |